Correlation between serum gastrin and cellular proliferation in Barrett's esophagus.

Abstract:

BACKGROUND:Patients with Barrett's esophagus (BE) are commonly treated with proton-pump inhibitors (PPIs) to minimize the exposure of esophageal mucosa to stomach acid. However, the use of these medications can lead to significant hypergastrinemia in a subset of patients, which is concerning due to the known tumorigenic and proliferative effects of gastrin. The present pilot study aims to investigate a potential correlation between serum gastrin and cellular proliferation in BE. METHODS:We performed a cross-sectional analysis of patients with nondysplastic BE on PPI therapy. Fasting serum gastrin was measured on the same day as esophageal biopsies were obtained. These biopsies were then stained with Ki-67 nuclear antibody. Pearson's correlation coefficient was calculated to assess the relationship between Ki-67 index and ln(gastrin). RESULTS:A total of 10 patients were included in the study. The mean age was 62.6 (±8.4) years and 5 patients were male. The median serum gastrin level was 45.2 pM (interquartile range [IQR] 33-113) and the median Ki-67 index was 49.6% (IQR 23-64). We found a statistically significant positive correlation between Ki-67 index and ln(gastrin) (r = 0.64; p = 0.05). CONCLUSIONS:In nondysplastic BE patients on PPI therapy, serum gastrin levels were significantly correlated with cellular proliferation. These pilot data lend support to a potential causal effect of gastrin on neoplastic progression in BE. Longitudinal studies of patients with BE are needed to determine whether hypergastrinemia is a risk factor for the development of dysplasia and adenocarcinoma or could be used as a biomarker for disease progression.

authors

Green DA,Mlynarczyk CM,Vaccaro BJ,Capiak KM,Quante M,Lightdale CJ,Abrams JA

doi

10.1177/1756283X10392444

subject

Has Abstract

pub_date

2011-03-01 00:00:00

pages

89-94

issue

2

eissn

1756-283X

issn

1756-2848

pii

10.1177_1756283X10392444

journal_volume

4

pub_type

杂志文章
  • Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions.

    abstract::Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X17722061

    authors: Kim HY,Park JW

    更新日期:2017-10-01 00:00:00

  • External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection.

    abstract:Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820977385

    authors: van Rossen TM,van Dijk LJ,Heymans MW,Dekkers OM,Vandenbroucke-Grauls CMJE,van Beurden YH

    更新日期:2021-01-09 00:00:00

  • Diagnostic accuracy of i-scan image enhancement for real-time endoscopic diagnosis of small colorectal polyps: a meta-analysis.

    abstract:Objective:i-Scan is a digital image enhancement technology, reported to improve diagnostic performance during endoscopy. Previous studies have investigated the accuracy of i-scan for distinguishing between neoplastic and non-neoplastic colonic polyps and suggested diagnostic accuracy close to that required for use in r...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284818814948

    authors: Glover B,Patel N,Ashrafian H,Teare J

    更新日期:2018-12-06 00:00:00

  • Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND:Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS:Patients received o...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X17726087

    authors: Cash BD,Pimentel M,Rao SSC,Weinstock L,Chang L,Heimanson Z,Lembo A

    更新日期:2017-09-01 00:00:00

  • The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study.

    abstract:Background:Nonalcoholic fatty liver disease (NAFLD) is correlated with low-grade inflammation and dietary habits. Until today, there have been limited epidemiologic data assessing the role of diet's inflammatory potential on NAFLD. The aim was to evaluate the relationship between an anti-inflammatory diet, as reflected...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819858039

    authors: Tyrovolas S,Panagiotakos DB,Georgousopoulou EN,Chrysohoou C,Skoumas J,Pan W,Tousoulis D,Pitsavos C

    更新日期:2019-06-23 00:00:00

  • Decision model analyses of upper endoscopy for gastric cancer screening and preneoplasia surveillance: a systematic review.

    abstract:Aims:Gastric cancer (GC) is the third leading cause of cancer death worldwide, but the burden of disease is not distributed evenly. GC screening routinely occurs in some high-incidence regions/countries and is generally cost-effective, which is attributed largely to the associated GC mortality reduction. In regions of ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820941662

    authors: Canakis A,Pani E,Saumoy M,Shah SC

    更新日期:2020-07-16 00:00:00

  • Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn's disease.

    abstract:Background:Recent evidence has shown that the complete blood count (CBC) is abnormal in patients with Crohn's disease (CD). We aimed to investigate an effective CBC parameter and explore its impact on disease activity in a large CD cohort. Methods:We performed a retrospective analysis of patients with established CD w...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820979442

    authors: Chen R,Li L,Chao K,Hong M,Cao Q,Ye L,Zhou G,Fang X,Guo H,Cao X,Ye X,Zeng Z,Chen M,Zhang S

    更新日期:2020-12-21 00:00:00

  • Hereditary pancreatitis for the endoscopist.

    abstract::Hereditary pancreatitis shares a majority of clinical and morphologic features with chronic alcoholic pancreatitis, but may present at an earlier age. The term hereditary pancreatitis has primarily been associated with mutations in the serine protease 1 gene (PRSS1) which encodes for cationic trypsinogen. PRSS1 mutati...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X12467565

    authors: Patel MR,Eppolito AL,Willingham FF

    更新日期:2013-03-01 00:00:00

  • The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment.

    abstract::Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X15587481

    authors: Lam BP,Jeffers T,Younoszai Z,Fazel Y,Younossi ZM

    更新日期:2015-09-01 00:00:00

  • Secondary causes of nonalcoholic fatty liver disease.

    abstract::Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease rangi...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11430859

    authors: Kneeman JM,Misdraji J,Corey KE

    更新日期:2012-05-01 00:00:00

  • Bilio-pancreatic endoscopy during COVID-19 pandemic.

    abstract::On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820935187

    authors: Bove V,Schepis T,Boškoski I,Landi R,Orlandini B,Pontecorvi V,Familiari P,Tringali A,Perri V,Costamagna G

    更新日期:2020-06-24 00:00:00

  • Host-targeting therapies for hepatitis C virus infection: current developments and future applications.

    abstract::Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with consider...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284818759483

    authors: Crouchet E,Wrensch F,Schuster C,Zeisel MB,Baumert TF

    更新日期:2018-03-21 00:00:00

  • Targeting mucosal healing in Crohn's disease: what the clinician needs to know.

    abstract::In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284819856865

    authors: Klenske E,Bojarski C,Waldner M,Rath T,Neurath MF,Atreya R

    更新日期:2019-06-14 00:00:00

  • Clostridium difficile infection: management strategies for a difficult disease.

    abstract::Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X13508519

    authors: Khanna S,Pardi DS

    更新日期:2014-03-01 00:00:00

  • PillCam COLON capsule endoscopy: recent advances and new insights.

    abstract::Capsule endoscopy for the colon was introduced to allow an alternative screening method to the invasive classic colonoscopy. The results of initial studies have shown inferior detection rates of colonic polyps by the colon capsule. In this paper we aim to review and summarize the recent advances in wireless capsule en...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11401645

    authors: Adler SN,Metzger YC

    更新日期:2011-07-01 00:00:00

  • Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.

    abstract::Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple cli...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X16638833

    authors: Kopylov U,Seidman E

    更新日期:2016-07-01 00:00:00

  • Effective treatment of chronic radiation proctitis using radiofrequency ablation.

    abstract::Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283x08103341

    authors: Zhou C,Adler DC,Becker L,Chen Y,Tsai TH,Figueiredo M,Schmitt JM,Fujimoto JG,Mashimo H

    更新日期:2009-01-01 00:00:00

  • Review of the epidemiology and burden of ulcerative colitis in Latin America.

    abstract::The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incide...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820931739

    authors: Kotze PG,Steinwurz F,Francisconi C,Zaltman C,Pinheiro M,Salese L,Ponce de Leon D

    更新日期:2020-07-09 00:00:00

  • Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

    abstract::Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11428502

    authors: Kelesidis T,Pothoulakis C

    更新日期:2012-03-01 00:00:00

  • Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.

    abstract::Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X16658251

    authors: Liu X,Yang Z,Latchoumanin O,Qiao L

    更新日期:2016-11-01 00:00:00

  • Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.

    abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820938960

    authors: Chen B,Gao X,Zhong J,Ren J,Zhu X,Liu Z,Wu K,Kalabic J,Yu Z,Huang B,Kwatra N,Doan T,Robinson AM,Chen MH

    更新日期:2020-07-16 00:00:00

  • Erratum for PMID 21180585.

    abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 已发布勘误

    doi:10.1177/1756283X10363751

    authors:

    更新日期:2012-09-01 00:00:00

  • The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

    abstract::Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the accumulation of vast amounts of knowledge on the genomic profiles of biliary tract cancer (BTC). Recent largescale molecular profiling studies have not only highlighted genomic differences characterizing tumors of the intrahe...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X17698090

    authors: Lee H,Ross JS

    更新日期:2017-06-01 00:00:00

  • Automated endoscopic detection and classification of colorectal polyps using convolutional neural networks.

    abstract:Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820910659

    authors: Ozawa T,Ishihara S,Fujishiro M,Kumagai Y,Shichijo S,Tada T

    更新日期:2020-03-20 00:00:00

  • Prophylaxis of hepatitis B infection in solid organ transplant recipients.

    abstract::Rates of transmission of hepatitis B virus (HBV) infection from organ donors with HBV markers to recipients along with reactivation of HBV during immunosuppression following transplantation have fallen significantly with the advent of hepatitis B immune globulin (HBIg) and effective antiviral therapy. Although the ava...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X13487942

    authors: John S,Andersson KL,Kotton CN,Hertl M,Markmann JF,Cosimi AB,Chung RT

    更新日期:2013-07-01 00:00:00

  • Certolizumab pegol for the treatment of Crohn's disease.

    abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11413315

    authors: Schreiber S

    更新日期:2011-11-01 00:00:00

  • Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

    abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X08094880

    authors: Lee YC,Liou JM,Wu MS,Wu CY,Lin JT

    更新日期:2008-09-01 00:00:00

  • Optimal use of biologics in the management of Crohn's disease.

    abstract::Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new opt...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X09357579

    authors: Panaccione R,Ghosh S

    更新日期:2010-05-01 00:00:00

  • Chinese herbal medicine for functional dyspepsia: systematic review of systematic reviews.

    abstract:Background:Pharmacotherapy, including prokinetics and proton pump inhibitors for functional dyspepsia (FD) have limited effectiveness, and their safety has been recently questioned. Chinese herbal medicine (CHM) could be considered as an alternative. A systematic review (SR) of SRs was performed to evaluate the potenti...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284818785573

    authors: Chu MHK,Wu IXY,Ho RST,Wong CHL,Zhang AL,Zhang Y,Wu JCY,Chung VCH

    更新日期:2018-07-16 00:00:00

  • Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

    abstract::Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X10369922

    authors: Sanger GJ,Chang L,Bountra C,Houghton LA

    更新日期:2010-09-01 00:00:00